title: Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.
abstract: There has been a recent expansion of vaccination and immunotherapeutic strategies from controlling infectious diseases to the targeting of non-infectious conditions including neurodegenerative disorders. In addition to conventional vaccine and immunotherapeutic modalities, gene-based methods that express antigens for presentation to the immune system by either live viral vectors or non-viral naked DNA plasmids have been developed and evaluated. This mini-review/commentary summarizes the advantages and disadvantages, as well as the research findings to date, of both of these gene-based vaccination approaches in terms of how they can be targeted against appropriate antigens within the Alzheimer and Parkinson disease pathogenesis processes as well as potentially against targets in other neurodegenerative diseases. Most recently, the novel utilization of these viral vector and naked DNA gene-based technologies includes the delivery of immunoglobulin genes from established biologically active monoclonal antibodies. This modified passive immunotherapeutic strategy has recently been applied to deliver passive antibody immunotherapy against the pathologically relevant amyloid β protein in Alzheimer disease. The advantages and disadvantages of this technological application of gene-based immune interventions, as well as research findings to date are also summarized. In sum, it is suggested that further evaluation of gene based vaccines and immunotherapies against neurodegenerative diseases are warranted to determine their potential clinical utility.
authors.affiliation: a Department of Molecular Medicine ; Morsani College of Medicine; University of South Florida ; Tampa , FL USA.
authors.forename: Jeremy J
authors.initials: JJ
authors.lastname: Kudrna
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Ugen
mesh_terms: D000818:Animals; D004337:Drug Carriers; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D056747:Immunomodulation; D008822:Mice, Transgenic; D019636:Neurodegenerative Diseases / Q000628:therapy*; D010957:Plasmids; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D014780:Viruses
chemical_list: D004337:Drug Carriers; D019444:Vaccines, DNA; D014765:Viral Vaccines
keywords: Alzheimer disease; DNA vaccines; Parkinson disease; passive antibody immunotherapy; viral vector vaccines